Fankai Meng

Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China

Papers on Lattice

Total citations

Topics

h-index

Publication activitypapers/week, last 8 weeks

Frequent co-authors

Zekai Mao (1)Juan Peng (1)Yang Cao (1)Nan Wang (1)

Papers (1)

Feb 13, 2026

Immunotherapy Research Center for Hematologic Diseases of Hubei ProvinceFeb 13, 2026·also HUST

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Dual-target CD19/CD22 CAR-T-cell therapy, especially when combined with ASCT, demonstrates sustained clinical benefit and may overcome the negative prognostic impact of TP53 alterations in relapsed/refractory aggressive B-NHL.

Zekai Mao, Juan Peng, Yang Cao +11

Search

Fankai Meng

Publication activitypapers/week, last 8 weeks

Frequent co-authors

Papers (1)